PLYMOUTH, Mass.--(BUSINESS WIRE)--Nov 2, 2023--IDRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment with purpose-built precision therapies, today announced preliminary clinical data from the dose escalation portion of the company鈥檚 ongoing Phase 1 ...
LONDON--(BUSINESS WIRE)--Nov 2, 2023--Prokarium, a biopharmaceutical company at the forefront of applying synthetic biology to create novel cancer treatments, today announces that the U.S. Food and Drug Administration (FDA) has granted the company's Investigational New Drug (IND) application ...
BERKELEY, Calif.--(BUSINESS WIRE)--Nov 1, 2023--IMVARIA Inc., a health tech company pioneering AI-driven digital biomarker solutions, today announced a collaboration through a know-how agreement with Mayo Clinic to develop AI designed to significantly improve the analysis and understanding of ...
SAN DIEGO--(BUSINESS WIRE)--Nov 1, 2023--Calidi Biotherapeutics, Inc. (NYSE American: CLDI or 鈥淐alidi鈥�), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced two key promotions from the clinical leadership team and the appointment ...
RAHWAY, N.J.--(BUSINESS WIRE)--Nov 1, 2023--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck鈥檚 anti-PD-1 therapy, in combination with gemcitabine and cisplatin, for the ...
RAHWAY, N.J.--(BUSINESS WIRE)--Nov 1, 2023--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYNOTE-564 trial evaluating KEYTRUDA, Merck鈥檚 anti-PD-1 therapy, met its key secondary endpoint of overall survival (OS), for the adjuvant ...